/PRNewswire/ -- PostEra, a biotechnology company that specializes in artificial intelligence for preclinical drug discovery, announced today that it will collaborate with Amgen, one of the world's leading biotech companies, on a range of multi-targeted projects.
A collaboration between PostEra and Amgen will use PostEra's artificial intelligence platform, Proton, an innovative approach to generative chemistry and synthesis-aware design, as well as Amgen's drug discovery experience, to advance up to five small molecule programs. Upon entering into a certain number of programs into the collaboration, Amgen will have the option of utilizing some of PostEra's key artificial intelligence technologies for its own programs outside the collaboration once the number of programs enters the collaboration.
This agreement includes up-front funding, milestone payments, as well as royalties on any products that result from the collaboration that are approved.
'We are very excited to collaborate with Amgen, which has a wealth of expertise across multiple therapeutic areas and has a long history of tackling some of biology's most difficult targets,' says Dr Alpha Lee, CSO of PostEra, in a statement.. In spite of the fact that the Proton platform has been validated numerous times over the past few years, it is still capable of effectively handling even the most challenging small molecule drug discovery programs.. In our opinion, artificial intelligence (AI) has the potential to significantly impact drug discovery, but we are also aware of the hype that surrounds it as well.. It is for this reason that PostEra has worked hard to demonstrate the value of Proton on real discovery programs, with multiple partners across a wide range of therapeutic areas", explained Aaron Morris, CEO of PostEra.
It is for this reason that PostEra has worked hard to demonstrate the value of Proton on real discovery programs, with multiple partners across a wide range of therapeutic areas", explained Aaron Morris, CEO of PostEra.
This is the story of PostEra, a machine learning startup that was founded in 2019 and is based on pioneering academic research conducted by its founding scientists.. Through the industrialization of the design-make-test cycle of medicinal chemistry, PostEra's technology can address some of the key challenges in small molecule drug discovery. PostEra advances small molecule programs through partnerships with biopharmaceutical companies as well as its own internal pipeline of small molecules. Across a number of biopharmaceutical partners, the company has closed AI partnerships worth $1Bn. In addition to this, PostEra launched and led the largest open-source drug discovery effort in the world; COVID Moonshot;
In addition to this, PostEra launched and led the largest open-source drug discovery effort in the world; COVID Moonshot;
PostEra is the source of this information
PostEra, a biotechnology company specializing in artificial intelligence for the discovery of preclinical drugs, today announced it has entered into a multi-target collaboration with ...
If you'd like to receive PRN's top stories and curated news delivered to your inbox on a weekly basis, sign up here!

Source prnewswire